Skip to main content
Caplight Logo









Igyxos Biotherapeutics

Igyxos Biotherapeutics

Private
NouzillyHealthcare & Life Scienceshttps://www.igyxos.com/

Last Round

Grant

Oct 2, 2025

Total Funding Raised

$20.58M

Company Overview

Igyxos Biotherapeutics is a biotechnology company that develops monoclonal antibody-based therapeutics to treat infertility in men and women.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

biotechnologymonoclonal antibodyinfertility treatmentfertility techfollicle stimulating hormoneFSHassisted reproductive technologyARTIVFclinical-stage biotechdrug discoveryreproductive healthspermatogenesisovarian stimulationbiologics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Igyxos Biotherapeutics Comparables

Compare Igyxos Biotherapeutics with similar companies based on industry and business-model similarity.

Igyxos Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Oxolife
78%
Granata Bio
76%
Merck
73%

Igyxos Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 2, 2025
VC RoundNov 14, 2023
DebtNov 14, 2023
Series AMar 21, 2019

Key People

Founding team and executive leadership

Florent Ferré

Chief Executive Officer

Executive Team

Thierry Ziegler

Chief Operating Officer

Executive Team

Igyxos Biotherapeutics Investors

Notable investors and investment history

Igyxos Biotherapeutics investors
InvestorRounds
Social Impact EnterprisesVC Round
Sofimac InnovationSeries A
GO CapitalVC Round, Series A
Sofimac Investment ManagersVC Round
BpifranceDebt, VC Round, Grant, Series A
UI InvestissementVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Monthly visitors grew 1871% MoM, reaching 2.5K.

  • Nov 14, 2023

    $12.3M raised from Sofimac, UI Investissement, GO Capital, Bpifrance, and Social Impact Enterprises.

Igyxos Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Igyxos Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Igyxos Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNouzilly
Employee Range16
Year Founded2017
Last FundingOct 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?